Conjugated To Proteinaceous Toxin Or Fragment Thereof (e.g., Conjugated To Diphtheria Toxin, Pseudomonas Exotoxin, Ricin, Gelonin, Abrin, Etc.) Patents (Class 424/183.1)
-
Patent number: 6924360Abstract: The present invention relates generally to the generation and characterization of anti-MUC18 monoclonal antibodies. The invention further relates to the use of such anti-MUC18 antibodies in the diagnosis and treatment of disorders associated with increased activity of MUC18, in particular, tumors, such as melanomas.Type: GrantFiled: December 26, 2002Date of Patent: August 2, 2005Assignee: Abgenix, Inc.Inventors: Larry L. Green, Menashe Bar-Eli
-
Patent number: 6921533Abstract: Monoclonal antibodies and method for ameliorating an immune response disorder. The monoclonal antibodies are specific for an epitope present on the leukocyte adhesion receptor ?-chain.Type: GrantFiled: January 16, 2001Date of Patent: July 26, 2005Assignee: The Johns Hopkins University School of MedicineInventor: James E. Hildreth
-
Patent number: 6919079Abstract: The present invention generally relates to a new approach for the therapy of allergic responses, based on targeted elimination of cells expressing the Fc?RI receptor by a chimeric cytotoxin Fc2?-3-PE40. A sequence encoding amino acids 301-437 of the Fc region of the mouse IgE molecule was genetically fused to PE40—a truncated form of PE lacking the cell binding domain. The chimeric protein, produced in E. coli, specifically and efficiently kills mouse mast cell lines expressing the Fc?RI receptor, as well as primary mast cells derived from bone marrow. The present invention provides a chimeric protein for targeted elimination of Fc?RI expressing cells especially useful for the therapy of allergic responses. The said chimeric protein is comprised of a cell targeting moiety for Fc?RI expressing cells and a cell killing moiety. The preferred killing moiety is the bacterial toxin Pseudomonas exotoxin (PE). This Pseudomonas exotoxin is a product of Pseudomonas aeruginosa.Type: GrantFiled: December 18, 1996Date of Patent: July 19, 2005Assignee: Yissum Research Company of the Hebrew University of JerusalemInventors: Ala Fishman, Shai Yarkoni, Haya Lorberboumgalski
-
Patent number: 6893625Abstract: A chimeric antibody with human constant region and murine variable region, having specificity to a 35 kDA polypeptide (Bp35(CD20)) expressed on the surface of human B cells, methods of production, and uses.Type: GrantFiled: August 1, 2000Date of Patent: May 17, 2005Assignee: Royalty Pharma Finance TrustInventors: Randy R. Robinson, Alvin Y. Liu, Jeffrey A. Ledbetter
-
Patent number: 6863887Abstract: The present invention relates to the identification of a novel role of CXCR-4 in cell transformation and aberrant cellular proliferation. In particular, the present invention relates to the altered gene expression of CXCR-4 in a number of primary tumors and cell lines derived from tumors, in addition to, the altered gene expression of ligands for CXCR-4. Further, the present invention relates, in part, to the Applicants' surprising discovery that the inhibition of CXCR-4 gene expression or the inhibition of CXCR-4 activity in transformed cells reverses the transformed phenotype.Type: GrantFiled: March 29, 1999Date of Patent: March 8, 2005Assignee: Northwest Biotherapeutics, Inc.Inventors: Bridgette Murphy, Alton L. Boynton, Anil Sehgal, Gerald P. Murphy
-
Patent number: 6855513Abstract: The invention provides methods for identifying a modulator of quorum sensing signaling in bacteria, and for identifying a quorum sensing controlled gene in bacteria. In addition, the invention provides quorum sensing controlled genetic loci in Pseudomas aeruginosa. Novel indicator strains and vectors for engineering the strains for use in the method of the invention are also provided.Type: GrantFiled: September 1, 2000Date of Patent: February 15, 2005Assignees: University of Iowa Research Foundation, Vertex Pharmaceuticals (San Diego) LLCInventors: Marvin Whiteley, Kimberly M. Lee, E. Peter Greenberg, Ute Muh
-
Patent number: 6843989Abstract: The present invention relates to methods and compositions for the prevention and treatment of cancer, inflammatory diseases and disorders or deficiencies of the immune system. The methods of the invention comprise administering a CD40 binding protein that potentiates the binding of CD40 to CD40 ligand.Type: GrantFiled: November 28, 2000Date of Patent: January 18, 2005Assignee: Seattle Genetics, Inc.Inventors: Clay B. Siegall, Alan F. Wahl, Joseph A. Francisco, Henry Perry Fell, Jr.
-
Patent number: 6835818Abstract: This invention is directed to mutant SPE-C toxins or fragments thereof, vaccine and pharmaceutical compositions, and methods of using the vaccine and pharmaceutical compositions. The preferred SPE-C toxin has at least one amino acid change and is substantially non-lethal compared with the wild type SPE-C toxin. The mutant SPE-C toxins can form vaccine compositions useful to protect animals against the biological activities of wild type SPE-C toxin.Type: GrantFiled: July 14, 1999Date of Patent: December 28, 2004Assignee: Regents of the University of MinnesotaInventors: Patrick M. Schlievert, Douglas Ohlendorf, David T. Mitchell, Pamala J. Gahr
-
Patent number: 6824793Abstract: Compositions are provided which include hyaluronic acid derivatives in combination with vaccine antigens, and optionally adjuvants, for mucosal delivery. Also provided are methods of making the compositions, as well as methods of immunization using the same.Type: GrantFiled: November 28, 2000Date of Patent: November 30, 2004Assignees: Chiron Corporation, Fidia Advanced Biopolymers SrlInventors: Derek O'Hagan, Alessandra Pavesio
-
Patent number: 6808930Abstract: An agent comprising a protein complex comprising an oligomeric form of &agr;-lactalbumin (MAL) and a further reagent which is combined with MAL such that it is carried into the nucleoplasm of cells which are susceptible to MAL. Agents of the type, where the further reagent is a therapeutic or labelling reagent, can be used in diagnosis and therapy in particular of cancer.Type: GrantFiled: August 30, 2000Date of Patent: October 26, 2004Inventors: Catharina Svanborg, Per Anders Hakansson
-
Patent number: 6809184Abstract: Mesothelin is a differentiation antigen present on the surface of ovarian cancers, mesotheliomas and several other types of human cancers. Because among normal tissues, mesothelin is only present on mesothelial cells, it represents a good target for antibody mediated delivery of cytotoxic agents. The present invention is directed to anti-mesothelin antibodies, including Fv molecules with particularly high affinity for mesothelin, and immunoconjugates employing them. Also described are diagnostic and therapeutic methods using the antibodies. The anti-mesothelin antibodies are well-suited for the diagnosis and treatment of cancers of the ovary, stomach, squamous cells, mesotheliomas and other malignant cells expressing mesothelin.Type: GrantFiled: September 27, 2000Date of Patent: October 26, 2004Assignee: The United States of America as represented by the Secretary of the Department of Health and Human ServicesInventors: Ira H. Pastan, Partha S. Chowdhury
-
Patent number: 6783758Abstract: The invention features a method for diagnosing a malignant neoplasm in a mammal by contacting a bodily fluid from the mammal with an antibody which binds to an human aspartyl (asparaginyl) beta-hydroxylase (HAAH) polypeptide and methods of treating malignant neoplasms by inhibiting HAAH.Type: GrantFiled: July 11, 2001Date of Patent: August 31, 2004Assignee: Rhode Island HospitalInventors: Jack R. Wands, Suzanne M. de la Monte, Nedim Ince, Rolf I. Carlson
-
Patent number: 6780866Abstract: A pharmaceutical analgesic composition comprising an opioid analgesic agent and a compound that binds to the SS1 or SS2 subunit of a sodium channel, such as tetrodotoxin and saxitoxin, and analogs thereof. Administration of an opioid analgesic agent and a compound that binds to the SS1 or SS2 subunit of a sodium channel, such as tetrodotoxin and saxitoxin, and analogs thereof, produces analgesia in the treatment of pain in mammals.Type: GrantFiled: February 5, 2002Date of Patent: August 24, 2004Assignee: WEX Medical Instrumentation Co., Ltd.Inventors: Baoshan Ku, Frank Hay Kong Shum
-
Patent number: 6780413Abstract: Compositions and methods for treatment of focal muscle spasms. Immunotoxin conjugates comprise a toxin conjugated to an antibody reactive to a muscle specific antigen.Type: GrantFiled: November 7, 2001Date of Patent: August 24, 2004Assignee: The United States of America as represented by the Department of Health and Human ServicesInventors: Jonathan S. Hott, Richard J. Youle, Mark Hallett, Marinos C. Dalakas
-
Patent number: 6774218Abstract: This invention is directed to mutant SPE-C toxins or fragments thereof, vaccine and pharmaceutical compositions, and methods of using the vaccine and pharmaceutical compositions. The preferred SPE-C toxin has at least one amino acid change and is substantially non-lethal compared with the wild type SPE-C toxin. The mutant SPE-C toxins can form vaccine compositions useful to protect animals against the biological activities of wild type SPE-C toxin.Type: GrantFiled: June 18, 1999Date of Patent: August 10, 2004Assignee: Regents of the University of MinnesotaInventors: Patrick M. Schlievert, Douglas Ohlendorf, David T. Mitchell, Pamela Gahr
-
Patent number: 6733743Abstract: Primitive or progenitor hematologic cancer cells have been implicated in the early stages and development of leukemia and malignant lymphoproliferative disorders, including acute myelogenous leukemia (AML), chronic myelogenous leukemia (CML) and chronic lymphoid leukemia (CLL). Interleukin-3 receptor alpha chain (IL-3R&agr; or CD123) is strongly expressed on progenitor hematologic cancer cells, but is virtually undetectable on normal bone marrow cells. The present invention provides methods of impairing progenitor hematologic cancer (e.g., leukemia and lymphomic) cells by selectively targeting cells expressing CD123. These methods are useful in the detection and treatment of leukemias and malignant lymphoproliferative disorders. Also provided are compounds useful for selectively binding to CD123 and impairing progenitor hematologic cancer cells. These compounds may include cytotoxic moieites such as, for example, radioisotopes or chemotherapeutics.Type: GrantFiled: March 6, 2001Date of Patent: May 11, 2004Assignee: University of Kentucky Research FoundationInventor: Craig Jordan
-
Patent number: 6680296Abstract: The invention relates to a novel ribosome-binding protein derived from Bougainvillea speotabilis having a molecular weight of about 26,000 daltons by polyacrylamide gel electrophoresis under reducing and non-reducing conditions, a ph of about 9.0, and further comprising a specified amino-terminal amino acid sequence, as well as to a conjugate of said protein with a targeting ligand, such as an antibody, to form an immunotoxin. The protein and the conjugate are useful in therapy, for example in the control of tumour calls or viruses.Type: GrantFiled: March 10, 2000Date of Patent: January 20, 2004Assignee: Tanox Pharma B.V.Inventors: Fiorenzo Stirpe, Andrea Bolognesi
-
Patent number: 6676941Abstract: Disclosed are antibodies that specifically inhibit VEGF binding to only one (VEGFR2) of the two VEGF receptors. The antibodies effectively inhibit angiogenesis and induce tumor regression, and yet have improved safety due to their specificity. The present invention thus provides new antibody-based compositions, methods and combined protocols for treating cancer and other angiogenic diseases. Advantageous immunoconjugate and prodrug compositions and methods using the new VEGF-specific antibodies are also provided.Type: GrantFiled: November 30, 2001Date of Patent: January 13, 2004Assignee: Board of Regents, The University of Texas SystemInventors: Philip E. Thorpe, Rolf A. Brekken
-
Patent number: 6676924Abstract: A humanized monoclonal antibody, comprising the complementarity-determining regions of a parental murine Class III, anti-CEA monoclonal antibody engrafted to the framework regions of a heterologous antibody, wherein the humanized monoclonal antibody retains the binding specificity of, but is less immunogenic in a heterologous host than, the parental murine monoclonal antibody A preferred murine Class III, anti-CEA monoclonal antibody is the MN-14 antibody and the preferred heterologous antibody is from a human. Also provided are DNA constructs and vectors for producing the humanized monoclonal antibodies, and diagnostic and therapeutic conjugates using same.Type: GrantFiled: February 22, 1999Date of Patent: January 13, 2004Assignee: Immunomedics, Inc.Inventors: Hans J. Hansen, Kathryn L. Armour
-
Patent number: 6669938Abstract: Immunoconjugates of an antibody to a 22 KD breast tumor associated antigen were prepared. Cytotoxic immunoconjugates such as gelonin-15A8 antibody conjugate are useful for treating proliferative cell diseases such as breast carcinoma and cervical carcinoma as well as other tumors which bear the 15A8 antigen. Detectably labeled compositions for diagnosis of such diseases are also disclosed.Type: GrantFiled: September 24, 1993Date of Patent: December 30, 2003Assignee: Research Development FoundationInventors: Michael G. Rosenblum, Renato Dulbecco, W. Ross Allen
-
Patent number: 6653084Abstract: The isolation, cloning and characterization of a human gene related to but distinct from the EGF receptor gene has been described. Nucleotide sequence of the gene and amino acid sequence of the polypeptide encoded by the gene have been determined. The use of the nucleic acid probes and antibodies having specific binding affinity with said polypeptide for diagnostic and therapeutic purposes has also been described.Type: GrantFiled: June 7, 1995Date of Patent: November 25, 2003Assignee: The United States of America as represented by the Department of Health and Human ServicesInventors: C. Richter King, Matthias H. Kraus, Stuart A. Aaronson
-
Patent number: 6652852Abstract: A chimeric antibody with human constant region and murine variable region, having specificity to a 35 kDA polypeptide (Bp35(CD20)) expressed on the surface of human B cells, methods of production, and uses.Type: GrantFiled: November 28, 2000Date of Patent: November 25, 2003Assignee: Royalty Pharma Finance TrustInventors: Randy R. Robinson, Alvin Y. Liu, Jeffrey A. Ledbetter
-
Patent number: 6645494Abstract: An immunotoxin molecule is described which comprises an antibody specific for human CD40L antigen located on the surface of a human cell, coupled to a toxin molecule or active fragment thereof, wherein the binding of the immunotoxin to the CD40L molecule results in the killing of the CD40L expressing cell. The toxin molecule is especially a type-1 ribosome inactivating protein, or an active fragment thereof. The immunotoxin can be used for the treatment of autoimmune diseases such as multiple sclerosis, rheumatoid arthritis and systemic lupus erythematosus, or T-cell malignancies.Type: GrantFiled: February 7, 2000Date of Patent: November 11, 2003Assignee: Tanox Pharma B.V.Inventors: Mark Boer De, Marcel Theodorus Hartog Den
-
Publication number: 20030206912Abstract: The present invention concerns fibroblast growth factor receptor 3 (FGFR3) as a novel marker for mesenchymal skeletal progenitor cells. By utilizing this novel marker it was possible both to identify and locate mesenchymal skeletal progenitor cells in a tissue, as well as to obtain a substantially pure culture of such cells. The pure culture of the mesenchymal skeletal progenitor cells may be used, optionally after various manipulations ex vivo, as an active ingredient in pharmaceutical compositions or implants for the purpose of bone and/or cartilage repair. FGFR3 may also be used as a marker for the identification and the localization of cartilage- and bone-derived tumors. Agents capable of binding to FGFR3 may also be used for targeting cytotoxic agents to cartilage- and bone-derived tumors.Type: ApplicationFiled: December 12, 2002Publication date: November 6, 2003Applicants: Yeda Research And Development Co., Ltd., Ramot Univ. Authority for applied Research and Industrial Development Ltd., both Israeli Cor.Inventors: Avner Yayon, Zvi Nevo
-
Patent number: 6638509Abstract: The present invention relates to a toxin conjugate in which a residue derived from a compound having an affinity for a target cell is bound to a toxin through a spacer comprising polyalkylene glycol and dipeptide.Type: GrantFiled: February 8, 2000Date of Patent: October 28, 2003Assignee: Kyowa Hakko Kogyo, Co., Ltd.Inventors: Toshiyuki Suzawa, Motoo Yamasaki, Satoru Nagamura, Hiromitsu Saito, So Ohta, Nobuo Hanai
-
Patent number: 6627197Abstract: Compositions and methods for selectively killing a cell containing a viral protease are disclosed. The composition is a variant of a protein synthesis inactivating toxin wherein a viral protease cleavage site is interposed between the A and B chains. The variant of the type II ribosome-inactivating protein is activated by digestion of the viral protease cleavage site by the specific viral protease. The activated ribosome-inactivating protein then kills the cell by inactivating cellular ribosomes. A preferred embodiment of the invention is specific for human immunodeficiency virus (HIV) and uses ricin as the ribosome-inactivating protein. In another preferred embodiment of the invention, the variant of the ribosome-inactivating protein is modified by attachment of one or more hydrophobic agents. The hydrophobic agent facilitates entry of the variant of the ribosome-inactivating protein into cells and can lead to incorporation of the ribosome-inactivating protein into viral particles.Type: GrantFiled: June 15, 2001Date of Patent: September 30, 2003Assignee: Bechtel BWXT Idaho, LLCInventors: William K. Keener, Thomas E. Ward
-
Patent number: 6613330Abstract: Toxin complexes and methods for preventing immune rejection of xenografts are provided. Cell toxins are coupled to carriers that display ligands which allow the complex to be recognized by antigen binding sites (i.e., specific B cell and T cell receptors) on the lymphocytes as the target cells responsible for the specific immune response. The toxin complexes interact with the specific receptors (antigen binding sites) on lymphocytes, and are internalized by these target cells. Once internalized, the toxin complex dissociates to release the cell toxin, which destroys the target cell. In one embodiment, the target cells are B lymphocytes and T lymphocytes, the antigen binding sites are anti-Gal B cell receptors and T cell receptors which interact with &agr;-gal epitopes displayed on an &agr;1-acid glycoprotein carrier. In other embodiments, the toxin complex is directed by the corresponding ligands to target cells responsible for autoimmune diseases in which the specificity of the autoantibodies is defined.Type: GrantFiled: July 27, 1999Date of Patent: September 2, 2003Assignee: Rush UniversityInventor: Uri Galili
-
Patent number: 6610294Abstract: This invention provides a method of inhibiting an autoimmune response in an animal suffering from an autoimmune disease selected from the group consisting of psoriasis, Lyme disease and hyper IgE syndrome which comprises administering to the animal, in an amount effective to treat the autoimmune disease, an antibody that binds specifically to a protein specifically recognized by monoclonal antibody 5c8 produced by the hybridoma having ATCC Accession No. HB 10916.Type: GrantFiled: October 20, 1994Date of Patent: August 26, 2003Assignee: The Trustees of Columbia University in the City of New YorkInventors: Seth Lederman, Leonard Chess, Michael J. Yellin
-
Publication number: 20030157093Abstract: Provided is a method of treating an autoimmune disease in an animal comprising administering to the animal an antibody-DT mutant immunotoxin which routes by the anti-CD3 pathway, or derivatives thereof, under conditions such that the autoimmune disease is treated. In a further embodiment, the invention provides a method of treating T cell leukemias or lymphomas in an animal comprising administering to the animal an antibody-DT mutant immunotoxin which routes by the anti-CD3 pathway, or derivatives thereof, under conditions such that the T cell leukemias or lymphomas are treated.Type: ApplicationFiled: September 3, 1999Publication date: August 21, 2003Inventors: DAVID M. NEVILLE, JR., JOSHUA E. SCHARFF, JERRY TODD THOMPSON, HUAIZHONG HU, SHENGLIN MA
-
Patent number: 6607725Abstract: A conjugate vaccine for Nontypeable Haemophilus influenzae comprising lipooligosaccharide from which esterified fatty acids have been removed conjugated to an immunogenic carrier. The vaccine is useful for prevention of otitis media and respiratory infections in mammals.Type: GrantFiled: February 20, 2001Date of Patent: August 19, 2003Assignee: The United States of America as represented by the Department of Health and Human ServicesInventors: Xin-Xing Gu, Chao-Ming Tsai, David J. Lim, John B. Robbins
-
Patent number: 6599505Abstract: The present invention provides novel immunotoxins and methods of treating neoplastic diseases. These immunotoxins are comprised of a conjugation of an antigen binding region exhibiting binding specificity for the CD33 protein and a cell growth modulator. The immunotoxins of the present invention specifically and selectively kill tumor cells that are characterized by the expression of CD33 antigen. Thus, the novel immunotoxins would be useful in treating human leukemias, both acute and chronic, and other myelodysplastic syndromes.Type: GrantFiled: February 19, 1998Date of Patent: July 29, 2003Assignee: Research Development FoundationInventor: Michael G. Rosenblum
-
Patent number: 6596536Abstract: An isolated antibody that specifically binds a peptide coded by a nucleotide sequence coding for a variable region of &agr; chain of an human T lymphocyte receptor, said nucleotide sequence having a nucleotide sequence chosen from any of: V&agr; segments having any one of the sequences SEQ ID Nos. 1 to 11 or J&agr; segments having one of the sequence SEQ ID Nos. 13 or 15 to 19 and hybridomas producing said antibodies.Type: GrantFiled: May 16, 1995Date of Patent: July 22, 2003Assignee: Aventis Pharma S.A.Inventors: Thierry Hercend, Frederic Triebel, Sergio Roman-Roman, Laurent Ferradini
-
Patent number: 6592872Abstract: The present invention provides a vaccine for inducing an immune response in mammal to a specific antigen, where the vaccine comprises a unit dose of a binary, cytotoxic T lymphocyte vaccine comprising an anthrax protective antigen and a full length protein antigen bound to a nontoxic anthrax protective antigen binding protein comprising at least about the first 250 amino acid residues of the lethal factor of Bacillus anthracis and less than all of the amino acid residues of the lethal factor. The present invention also provides a method of immunizing a mammal against an antigen using the vaccine, and a method of inducing antigen-presenting mammalian cells to present specific antigens via the MHC class I processing pathway.Type: GrantFiled: September 15, 1997Date of Patent: July 15, 2003Assignee: The United States of America as represented by the Department of Health and Human ServicesInventors: Kurt Klimpel, Theresa J. Goletz, Naveen Arora, Stephen H. Leppla, Jay A. Berzofsky
-
Publication number: 20030103987Abstract: The invention comprises a method of treating a patient with a disorder, characterized by an activating mutation in the Ras proto-oncogene, comprising contacting cells of said patient with a protein having the toxic activity of Clostridium sordellii toxin LT under conditions favoring inactivating of Ras by glucosylation of Ras′ threonine 35 in said cell. Said protein preferably is an immunotoxin which contains as a toxic domain the catalytic domain of toxin LT.Type: ApplicationFiled: July 31, 1998Publication date: June 5, 2003Inventors: CHRISTOPH VON EICHEL-STREIBER, PATRICE BOQUET, MONICA THELESTAM
-
Patent number: 6569447Abstract: The invention is a performance-enhancing feed supplement. The feed supplement is made up of a combination of spray-dried porcine plasma and spray-dried hyperimmune egg. The feed supplement is effectively administered to increase performance when weanling pigs and calves.Type: GrantFiled: March 23, 2001Date of Patent: May 27, 2003Assignee: Trouw Nutrition USA, LLCInventors: Julie A. Kisic, Thomas E. Shipp
-
Patent number: 6566500Abstract: The present invention provides methods to produce immunotoxins (ITs) and cytokines with a reduced ability to promote vascular leak syndrome (VLS). The invention also provides ITs and cytokines which have been mutated to lack amino acid sequences which induce VLS. Also disclosed are methods for producing peptides that inhibit the induction of VLS by ITs and cytokines. Also disclosed are peptides comprising the (x)D(y) sequence to promote the extravasation of other molecules. Toxins mutated in the (x)D(y) motif or active site residues are disclosed for used in vaccines.Type: GrantFiled: March 30, 2000Date of Patent: May 20, 2003Assignee: Board of Regents, The University of Texas SystemInventors: Ellen S. Vitetta, Victor F. Ghetie, Joan Smallshaw, Roxana G. Baluna
-
Patent number: 6562343Abstract: The present invention relates to methods and compositions for the treatment and diagnosis of immune disorders, especially T helper lymphocyte-related disorders. For example, genes which are differentially expressed within and among T helper (TH) cells and TH cell subpopulations, which include, but are not limited to TH0, TH1 and TH2 cell subpopulations are identified. Genes are also identified via the ability of their gene products to interact with gene products involved in the differentiation, maintenance and effector function of such TH cells and TH cell subpopulations. The genes identified can be used diagnostically or as targets for therapeutic intervention. In this regard, the present invention provides methods for the identification and therapeutic use of compounds as treatments of immune disorders, especially TH cell subpopulation-related disorders.Type: GrantFiled: December 15, 1999Date of Patent: May 13, 2003Assignee: Millennium Pharmaceuticals, Inc.Inventor: Douglas Adam Levinson
-
Patent number: 6534479Abstract: Disclosed is a method of inhibiting a neoplasm in a mammal, the method includes administering to the mammal a therapeutically effective amount of recombinant human alpha-fetoprotein.Type: GrantFiled: December 3, 1996Date of Patent: March 18, 2003Assignee: Martinex R & D Inc.Inventor: Robert A. Murgita
-
Publication number: 20030049264Abstract: The invention relates to an agent specific for peripheral sensory afferents. The agent may inhibit the transmission of signals between a primary sensory afferent and a projection neutron by controlling the release of at least one neurotransmitter or neuromodulator from the primary sensory afferent. The agent may be used in or as a pharmaceutical for the treatment of pain, particularly chronic pain.Type: ApplicationFiled: May 20, 2002Publication date: March 13, 2003Applicant: The Speywood Laboratory Ltd.Inventors: Keith Alan Foster, Michael John Duggan, Clifford Charles Shone
-
Patent number: 6524823Abstract: Liposomal conjugates having a clinically useful delivery vehicle linked to a biologically active species which acts to increase vascular permeability and expand blood volume at or in proximity to the tumor site are disclosed. The vehicle-linked species may be, for example, a vasoactive agent, a substance that recruits or amplifies a vasoactive species, a drug, or a pharmaceutical compound. Suitable biological species comprises peptides, lipids, carbohydrates, or their derivatives. Chemical or recombinant DNA methods suitable for linking the species to the vehicles are indicated. A therapy is disclosed which comprises administering the vasoactive conjugate and delivering a diagnostic agent or a therapeutic agent at an optimal time thereafter, when tumor vasculature is maximally affected.Type: GrantFiled: July 27, 2001Date of Patent: February 25, 2003Assignee: The University of Southern CaliforniaInventors: Alan L. Epstein, Michael Glovsky
-
Patent number: 6521230Abstract: Monoclonal antibodies to the CD25 antigen are characterized by the amino acid sequence of their hypervariable regions. Initially produced in murine form, they may be converted to chimeric or humanized forms, immunoconjugates or antibody fragments (generally described as binding molecules). The products are useful for the prophylaxis or treatment of transplant rejection, paticularly in combination with other antibodies to activated T-cells, for example CD7 antibodies.Type: GrantFiled: March 14, 1991Date of Patent: February 18, 2003Assignees: Novartis AG, University College LondonInventors: Peter Lloyd Amlot, Arne Nalpon Akbar, Günther Heinrich, Salvatore Cammisuli
-
Publication number: 20020192223Abstract: The present invention relates to novel antibodies, antibody fragments and antibody conjugates and single-chain immunotoxins reactive with human carcinoma cells. More particularly, the antibodies, conjugates and single-chain immunotoxins of the invention include: a murine monoclonal antibody, BR96; a human/murine chimeric antibody, ChiBR96; a F(ab′)2 fragment of BR96; ChiBR96-PE, ChiBR96-LysPE40, ChiBR96 F(ab′)2-LysPE40 and ChiBR96 Fab′-LysPE40 conjugates and recombinant BR96 sFv-PE40 immunotoxin. These molecules are reactive with a cell membrane antigen on the surface of human carcinomas. The BR96 antibody and its functional equivalents, displays a high degree of selectivity for carcinoma cells and possess the ability to mediate antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity activity.Type: ApplicationFiled: February 12, 2001Publication date: December 19, 2002Inventors: Ingegerg Hellstrom, Karl Erik Hellstrom, Kim Folger Bruce, George J. Schreiber
-
Publication number: 20020187153Abstract: The present invention relates to immunotoxins that effectively kill malignant cells having a given marker. The immunotoxins are reagents that comprise internalizing antibodies conjugated to cytotoxic ribonucleases or fragments thereof. The internalizing antibodies are capable of binding with a chosen tumor cell, and thereby confer little non-specific toxicity to the immunotoxin in a host. The immunotoxins exhibit up to 2000-fold higher toxicity against malignant B cells than did the ribonuclease counterparts alone.Type: ApplicationFiled: November 7, 2001Publication date: December 12, 2002Applicant: Immunomedics, Inc.Inventor: David M. Goldenberg
-
Patent number: 6492498Abstract: The invention features fusion protein monomers, multimeric immunotoxic proteins, nucleic acids encoding fusion protein monomers, vectors containing the nucleic acids, and cells containing the vectors. Also encompassed by the invention are methods of killing pathogenic cells and making multimeric immunotoxic proteins.Type: GrantFiled: November 15, 1999Date of Patent: December 10, 2002Assignee: Regents of the University of MinnesotaInventors: Daniel A. Vallera, Bruce R. Blazar
-
Patent number: 6485932Abstract: Liquid compositions for intravenous administration that comprise an aqueous solution of immunoglobulin and methods of preparing such compositions are disclosed. The solution has a pH in the range of 5.0 to 5.8 and an ionic strength is the range 0.02 to 0.25. The liquid compositions are formulated so as to be stable upon storage such that the immunoglobulin does not substantially aggregate nor degrade and maintains acceptable levels of anti-complementary activity, PKA activity and kallikrein activity during storage for an extended period at a temperature in the range of 4° C. to 25° C.Type: GrantFiled: October 25, 1999Date of Patent: November 26, 2002Assignee: Common Services AgencyInventors: Ronald Vance McIntosh, Anne Gillian Welch
-
Patent number: 6468530Abstract: Polyspecific immunoconjugates and antibody composites that bind a multidrug transporter protein and an antigen associated with a tumor or infectious agent are used to overcome the multidrug resistant phenotype. These immunoconjugates and composites also can be used diagnostically to determine whether the failure of traditional chemotherapy is due to the presence of multidrug resistant tumor cells, multidrug resistant HIV-infected cells or multidrug resistant infectious agents.Type: GrantFiled: April 8, 1996Date of Patent: October 22, 2002Assignee: Immunomedics, Inc.Inventor: David M. Goldenberg
-
Patent number: 6464978Abstract: The present invention provides vaccines and a means of vaccinating a mammal so as to prevent or control specific T cell mediated pathologies or to treat the unregulated replication of T cells. The vaccine is composed of a T cell receptor (TCR) or a fragment thereof corresponding to a TCR present on the surface of T cells mediating the pathology. The vaccine fragment can be a peptide corresponding to sequences of TCRs characteristic of the T cells mediating said pathology. The vaccine is administered to the mammal in a manner that induces an immunologically effective response so as to affect the course of the disease. The invention additionally provides specific &bgr;-chain variable regions of the T cell receptor, designated V&bgr;6.2/3, V&bgr;6.5, V&bgr;2, V&bgr;5.1, V&bgr;13 and V&bgr;7, which are central to the pathogenesis of multiple sclerosis (MS).Type: GrantFiled: April 29, 1993Date of Patent: October 15, 2002Assignee: The Immune Response CorporationInventors: Steven W. Brostoff, Darcy B. Wilson, Lawrence R. Smith, Daniel P. Gold, Dennis J. Carlo
-
Publication number: 20020142000Abstract: Recombinant immunotoxin polypeptides are described comprising a CD3-binding domain and a Pseudomonas exotoxin mutant, and in particular, comprising a single chain (sc) Fv as the CD3-binding moiety. A preferred species of the invention comprises scFv(UCHT-1)-PE38. Also disclosed are methods for the preparation of said immunotoxins; functionally equivalent immunotoxins which are intermediates in the preparation of the immunotoxins of the invention, as well as polynucleotide and oligonucleotide intermediates; methods for the prevention and/or treatment of transplant rejection and induction of tolerance, as well as treatment of autoimmune and other immune disorders, using the immunotoxins or pharmaceutically acceptable salts thereof; and pharmaceutical compositions comprising the immunotoxins or pharmaceutically acceptable salts thereof.Type: ApplicationFiled: January 10, 2000Publication date: October 3, 2002Inventors: Mary Ellen Digan, Philip Lake, Richard Michael Wright
-
Patent number: 6455673Abstract: Disclosed are diphtheria toxin polypeptides having multiple mutations, which render the polypeptides useful as vaccines.Type: GrantFiled: February 16, 1999Date of Patent: September 24, 2002Assignee: President and Fellows of Harvard CollegeInventor: R. John Collier
-
Patent number: 6451545Abstract: Provided are a monoclonal antibody making it possible to detect a native fibrin monomer, which is produced at the initial state of blood coagulation, and soluble fibrin; a hybridoma; and an immunoassay for detecting the initial stage of blood coagulation with high sensitivity, quickly, using the monoclonal antibody. Using a fibrinogen analog in blood as an immune source, cell fusion is carried out to prepare a monoclonal antibody which is not reactive with fibrinogen and is specifically and simultaneously reactive with a native fibrin monomer (that is, a fibrin monomer which is present in a body fluid, in particular in blood, and is not solubilized) and soluble fibrin. The fibrin monomer analog is preferably fibrinogen treated with bathroxobin, which is a snake venom.Type: GrantFiled: February 17, 1999Date of Patent: September 17, 2002Assignee: Nissui Pharmaceutical Co., Ltd.Inventors: Seiji Tanaka, Akiei Hamano, Mamoru Umeda